The above study further demonstrated that RelA/p65 Ser536 phosphorylation blocks NF-κB p65 nuclear translocation and inhibits NF-κB p65 binding to the BCL2 promoter, leading to HCC apoptosis and cycle arrest to suppress tumor growth. The gene discussed is BCL2; the disease is hepatocellular carcinoma.